HAEMONETICS CORP 10-Q

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds Issuer Purchases of Equity Securities The following table provides information on the Company’s share repurchases during the second quarter of fiscal 2023: Total Number of Shares Purchased Average Price Paid per Share Total Number of Shares Purchased as Part of Publicly Announced Program Approximate Dollar Value of Shares that May Yet Be Purchased Under the Program (in millions)($) (1) July 3, 2022 – July 30, 2022 July 31, 2022 - August 27, 2022 786,164 (2) 786,164 August 28, 2022 – October 1, 2022 Total 786,164 $225.0 (1) In August 2022, the Company’s Board of Directors authorized the repurchase of up to $300.0 million of the Company’s common stock from time to time, based on market conditions, over the next three years. Under the Company’s share repurchase program, shares may be repurchased in accordance with applicable laws both on the open market, including under trading plans established pursuant to Rule 10b5-1 under the Exchange Act, and in privately negotiated transactions. (2) Following the Company’s announcement of the share repurchase program, in August 2022, the Company entered into an ASR with Citibank to repurchase $75.0 million of the Company’s common stock. Pursuant to the terms of the ASR, in August 2022, the Company paid Citibank $75.0 million in cash and received an initial delivery of 0.8 million shares of the Company's common stock based on a closing market price on the New York Stock Exchange on August 16, 2022 of $76.32. This initial delivery of shares represented approximately 80% of the notional amount of the ASR. The ASR was completed in November 2022 and approximately 0.2 million additional shares were delivered upon settlement. 32 Item 3. Defaults Upon Senior Securities Not applicable. Item 4. Mine Safety Disclosures Not applicable.